Mechanism identified for drug resistance in glioblastoma

Linda Liau elected to Taiwan’s Academia Sinica

Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.

July 12, 2024

Vol.50 No.28

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Cells in tumor microenvironment play critical role in effectiveness of rapalogs

For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now, a study by researchers at UT Southwestern Medical Center’s Kidney Cancer Program sheds light.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.

May 31, 2024

Vol.50 No.22

Clinical Roundup

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Glucose-driven histone lactylation promotes immunosuppressive activity in glioblastoma

The Wistar Institute assistant professor Filippo Veglia and team have discovered a key mechanism of how glioblastoma suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.

May 10, 2024

Vol.50 No.19

Mechanism identified for drug resistance in glioblastoma

YOU MAY BE INTERESTED IN

Linda Liau elected to Taiwan’s Academia Sinica

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Cells in tumor microenvironment play critical role in effectiveness of rapalogs

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Glucose-driven histone lactylation promotes immunosuppressive activity in glioblastoma

Renew today!

Subscriber content

Login